Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Short Sales in huge quantities. Major indexes below their average of 50 days
Black Friday, tomorrow?
The main chart, $15.19, good price to buy!
Red candle, pointing down, indicating low
In fallen!
Comparative analysis:ZLTQ Vs S&P 500 INDEX(Shorted)
Financial Time 7/30/2014
Markit short selling activity:Upgrade, from low to médium
http://markets.ft.com/research/Markets/Tearsheets/Summary?s=ZLTQ:NSQ
INDU, NASDAQ & SPX The three market indices at risk !
They are on the verge of falling below their average of 50 days high
One more fall and the market collapses!
I am glad for your money
Totally agree, lecorb and thanks for the heads up.
Had already shorted today at 21.85.
Company carried in 1st qtr biz (300 machines) into 2nd qtr, which reported yesterday.
Company also captured biz in the 2nd they planned for 3rd from existing customers (finite group).
Bottom line, next qtr will be significant drop-off.
They did all they could to glitz the 2nd and make new CEO look good- jammed biz into 2nd and stuffed the channel with 3rd qtr biz.
Very "creative" quarter reported, yesterday!
Sooner or later this short will work well.
MG
Market Cap (intraday)5: 814.99M .Enterprise Value (Jul 30, 2014)3: 587.51M .Slightly exaggerated the difference, no or yes?
The market is raving mad!!
36,834 shares in short sell, $21.87 12:55 hs
In fallen. Today or tomorrow!
The main chart,RSI(14)78 in shorted.Overbought
Imminent collapse!166,095 SHARES IN SHORT SELL $22.29 11:19 HS
Be carefull!!
http://stockcharts.com/h-sc/ui?s=ZLTQ&p=D&b=5&g=0&id=p26099102557&a=264845671
ZLTQ 7/21/14: Thomson Reuters/Verus downgrades ZELTIQ AESTHETICS INC (ZLTQ) from HOLD to SELL.
BY Investars Analyst Actions - public— 10:05 AM ET 07/21/2014
On July 21, 2014 Thomson Reuters/Verus downgraded ZELTIQ AESTHETICS INC (ZLTQ) from HOLD to SELL.
http://stockcharts.com/h-sc/ui?s=ZLTQ
$ZLTQ Sell Watch: Zeltiq Has Become Over-Speculated http://seekingalpha.com/article/1955641-sell-watch-zeltiq-has-become-over-speculated?source=yahoo
BUYOUT...1.2 million or more WATCH...the patent on this procedure alone is worth 1.2 or maybe double that...
UPGRADES coming...this is still soooo under the wirte...going to 26.00 real sooon....
Real slow board here. I like the pe here all because of bad pr over the past month. New vp the best is yet to come with this stock.
Hehe.. Shortys trapped!!!
Ok, I found it using a screener with predefined setting on Stockfetcher.com
I look for stuff that tanks,has dropped alot % wise and stuff near 52 week lows
Also watching MNLU check the chart!
How did you find this stock?
Nice *ss covering!
Yup,nice bounce,upgrade last week really helped
Cool,small bounce try,lets see
Hilary Cramer (GameChanger) put out a SELL alert yesterday afternoon. Things will not improve, at least for this week, IMO. She cited the economic outlook for 2012 was poor, and clinics were using cheaper options.
In today,guessing insider lockup expiration is some selling pressure,ipo 6 months ago
still falling today, too. Amazing.
RSI 14-has anyone seen a stock that oversold? Havent seen any change in the recommendation of the analyst I was following -though a couple other analysts obviously have
One of the surest things I've seen in this crazy stock world is the knee jerk overreaction to quarterlies-even if predicted eps is missed by 1c all else is ignored-and in this case analysts expected a loss thru 2012-how many startups make money out of the gate?
isnt that what the ipo was for ca Oct 24-which raised a lot of money to hold them over until they did make a profit. Dont remember what analysts eps target was but I thought it would be worse than this eps report.
ZELTIQ Aesthetics Announces Fourth Quarter and Full Year 2011 Financial Results
PrintAlert
Zeltiq Aesthetics, Inc. (MM) (NASDAQ:ZLTQ)
Intraday Stock Chart
Today : Tuesday 6 March 2012
Fourth Quarter Highlights
•$18.8 million revenues, up 51.6% year over year and 6.1% sequentially
•60,250 cycles shipped, up 158.0% year over year and 35.0% sequentially
•Procedure fees revenues comprised 40.0% of total revenues, compared to 18.7% in the fourth quarter of 2010 and 25.4% in the third quarter of 2011
•Installed base increased 19.1% sequentially to 967 systems as of December 31, 2011
ZELTIQ Aesthetics, Inc. (Nasdaq:ZLTQ) today announced financial results for the fourth quarter and full year ended December 31, 2011, and provided guidance for 2012.
President and Chief Executive Officer Gordie Nye said, "Our fourth quarter results complete an exciting year for ZELTIQ. We achieved 168% revenue growth for the full year 2011 and expanded our installed base to 967 systems worldwide, demonstrating strong demand for CoolSculpting. Our sales force and S.T.E.P. specialists are committed to enhancing each practice's branding and marketing to drive utilization. The robust growth observed in consumer interest and the resulting utilization of our installed base is reflected in our year-over-year and sequential growth of procedure fees during the fourth quarter. We will continue to focus on expanding our installed base to achieve critical mass while driving procedure fee growth as a percentage of total revenues to enhance gross margins. With the completion of our October 2011 IPO, we are now strongly positioned to execute our sales, marketing, and pipeline strategies, including the initiation of direct to consumer advertising to achieve category-pioneering and industry-leading growth."
"In February of 2012, we launched our consumer advertising campaign 'Let's Get Naked' in three initial markets: Austin, Charlotte and Phoenix. With its emphasis on CoolSculpting's positive effect on one's self confidence, 'Let's Get Naked' celebrates our technology's unique aspects with an impactful call-to-action. As we roll out the campaign on a broader basis in the fall of 2012, we expect it to generate strong brand awareness and loyalty, leading to more rapid growth in consumer interest and further utilization of our installed base. We continue to see early evidence that cold-induced, non-surgical fat layer reduction has broad appeal to the large aesthetic neophyte population and expect the power of this advertising campaign to help establish the CoolSculpting brand around the world."
"During the fourth quarter, we initiated our transition to direct sales in certain international markets, which delayed certain system sales in these markets. Additionally, in our NAF region, we observed a slower than normal end of year sales cycle due to a number of unanticipated product launches and trial offers that competed for physician capital equipment dollars. We expect these issues to work through the sales channel over time, and we have strengthened the focus and organization of our sales team to help neutralize these effects."
Fourth Quarter Financial Review
Total net revenues for the fourth quarter of 2011 were $18.8 million, consisting of $11.3 million of systems revenues and $7.5 million of procedure fees revenues. This compares to total net revenues of $12.4 million, consisting of $10.1 million of systems revenues and $2.3 million of procedure fees revenues in the fourth quarter of 2010. Third quarter 2011 revenues were $17.7 million, consisting of $13.2 million of systems revenues and $4.5 million of procedure fees revenues. Cycles shipped increased to 60,250 in the fourth quarter of 2011, compared to 23,357 in the fourth quarter of 2010 and 44,619 in the third quarter of 2011, driving procedure fees revenue growth on both a year-over-year and sequential basis.
Gross profit was $12.3 million, or 65.6% of revenues, in the fourth quarter of 2011, compared to gross profit of $6.5 million, or 52.6% of revenues in the fourth quarter of 2010. Third quarter 2011 gross profit was $10.4 million, or 58.9% of revenues. Both year-over-year and sequential increases in gross profit were driven by an increase in procedure fees revenues as a percentage of total revenues, as well as a decrease in the per unit manufacturing cost of systems.
Operating expenses for the fourth quarter of 2011 were $17.3 million, compared to $8.4 million in the fourth quarter of 2010 and $13.2 million in the third quarter of 2011. Both year-over-year and sequential increases were primarily the result of growth of our North American direct sales force, costs to develop advertising assets, collateral for practice marketing initiatives, and increased research and development costs.
Net loss for the fourth quarter of 2011 was $5.4 million, compared to $2.0 million in the fourth quarter of 2010 and $2.9 million in the third quarter of 2011. Net loss attributable to common stockholders for the fourth quarter of 2011 was $0.22 per share, compared to $3.29 per share in the fourth quarter of 2010, and $3.17 per share in the third quarter of 2011.
2012 Financial Guidance
For the full year 2012, ZELTIQ expects total revenues to be in the range of $90.0 million to $94.0 million, an expected growth rate of 32% to 38% year-over-year. Procedure fees revenues are expected to be in the range of 40% to 44% of total revenues. Full year 2012 gross margins are expected to be in the range of 65% to 66% of total revenues, driven by an anticipated increase in procedure fees as a percentage of total revenues and reduced manufacturing costs. Full year 2012 operating expenses are expected to be in the range of 81% to 83% of total revenues; and sales and marketing expenses are expected to be in the range of 50% to 55% of total revenues, reflecting the continued roll-out of our recently launched advertising campaign. Full year 2012 net loss margin is expected to be in the range of 15% to 17% of total revenues.
Conference Call
ZELTIQ Aesthetics will host a conference call for investors on March 6, 2012 at 8:00 a.m. EST. The dial-in numbers are (877) 280-7291 for domestic callers and (707) 287-9361 for international callers. A live webcast of the call will also be available from the Investor Relations section of www.coolsculpting.com. A webcast replay from today's call will also be available from the Investor Relations section of www.coolsculpting.com approximately two hours after the call and will be available for up to thirty days.
About ZELTIQ Aesthetics
ZELTIQ Aesthetics is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company's first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.
Forward-Looking Statements
This press release contains forward-looking statements relating to the company's current and future business operations and financial performance and condition. Any statements contained in this press release that are not of historical facts may be deemed to be forward-looking statements, including our financial guidance for fiscal 2012. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect the company's actual business operations and financial performance and condition. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, less than anticipated growth in the number of physicians electing to purchase CoolSculpting Systems, insufficient patient demand for CoolSculpting procedures, our failure to correctly estimate and control our future expenditures, and the failure of our sales and marketing plans to increase sales as well as those other risks and uncertainties set forth in our Quarterly Report on Form 10-Q for the quarterly period September 30, 2011, filed with the SEC on November 16, 2011. These forward-looking statements speak only as of the date of this press release. We expressly disclaim any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
ZELTIQ Aesthetics, Inc.
Unaudited Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
Three Months Ended December 31, Twelve Months Ended December 31,
2011 2010 2011 2010
Revenues $ 18,798 $ 12,398 $ 68,144 $ 25,461
Cost of revenues 6,469 5,881 26,101 12,295
Gross profit 12,329 6,517 42,043 13,166
Operating expenses:
Research and development 2,948 1,975 10,488 8,222
Sales and marketing 10,281 4,353 28,953 11,987
General and administrative 4,059 2,028 11,299 5,873
Total operating expenses 17,288 8,356 50,740 26,082
Loss from operations (4,959) (1,839) (8,697) (12,916)
Interest income (expense), net (9) (44) (93) (497)
Other income (expense), net (353) (102) (765) (120)
Loss before provision for income taxes (5,321) (1,985) (9,555) (13,533)
Provision for income taxes 48 -- 48 --
Net loss (5,369) (1,985) (9,603) (13,533)
Cumulative dividends on convertible preferred stock (408) (1,605) (5,099) (5,426)
Net loss attributable to common stockholders $ (5,777) $ (3,590) $ (14,702) $ (18,959)
Net loss per share attributable to common stockholders, basic and diluted $ (0.22) $ (3.29) $ (1.96) $ (20.19)
Weighted average shares of common stock outstanding used in computing net loss attributable to common stockholders—basic and diluted 25,846,891 1,090,056 7,506,282 939,028
ZELTIQ Aesthetics, Inc.
Unaudited Condensed Consolidated Balance Sheets
(In thousands)
December 31,
2011 2010
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 83,908 $ 12,667
Accounts receivable, net 4,941 613
Inventory 4,476 2,164
Restricted cash 255 425
Prepaid expenses and other current assets 2,385 993
Total current assets 95,965 16,862
Property and equipment, net 2,144 1,397
Intangible asset, net 7,882 1,024
Other assets 8 --
Total assets $105,999 $ 19,283
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES:
Accounts payable $ 4,925 $ 3,373
Accrued liabilities 6,014 3,770
Deferred revenue, net of deferred costs 375 691
Current portion of notes payable 310 1,334
Total current liabilities 11,624 9,168
Notes payable, net of current portion -- 262
Convertible preferred stock warrant liability -- 257
Other non-current liabilities 72 201
Total liabilities $ 11,696 $ 9,888
Convertible preferred stock -- 93,888
Total stockholders' equity (deficit) 94,303 (84,493)
Total liabilities, convertible preferred stock and stockholders' equity (deficit) $105,999 $ 19,283
CONTACT: Josh Brumm
ZELTIQ Aesthetics, Inc.
Chief Financial Officer
925-474-2500
Nick Laudico / Amy Glynn
The Ruth Group
646-536-7030 / 7023
nlaudico@theruthgroup.com
aglynn@theruthgroup.com
ZLTQ has amended their distribution contract with Advance Medical to extend it to 2018.
No, nothing that I've seen shows she's even a niece or related by marriage to the jerk. The only thing he's good for is shorting any stock he mentions, for the spikes.
Is this the same Hillary related to the the convict/weasel on MSNBC- jimmy-
ZELTIQ to Report Fourth Quarter 2011 Financial Results on March 6, 2012
Zeltiq Aesthetics, Inc. (MM) (NASDAQ:ZLTQ)
Today : Wednesday 15 February 2012
ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today plans to release its fourth quarter 2011 financial results on Tuesday, March 6, 2012 at 7:30 a.m. ET.
ZELTIQ will hold a conference call on Tuesday, March 6, 2012 at 8:00 a.m. ET to discuss the results. The dial-in numbers are (877) 280-7291 for domestic callers and (707) 287-9361 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.coolsculpting.com.
After the live webcast, the call will remain available on ZELTIQ's website, www.coolsculpting.com, through April 6, 2012. In addition, a telephonic replay of the call will be available until March 20, 2012. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the replay pin number 52321656.
About ZELTIQ Aesthetics
ZELTIQ Aesthetics is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. The Company's first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.
CONTACT: Josh Brumm
ZELTIQ Aesthetics, Inc.
Chief Financial Officer
925-474-2500
Nick Laudico / Amy Glynn
The Ruth Group
646-536-7030 / 7023
nlaudico@theruthgroup.com
aglynn@theruthgroup.com
ZELTIQ Aesthetics, Inc. Announces Management Transition
Chief Financial Officer to Retire; Joshua Brumm Named Chief Financial Officer
Pleasanton, Calif. – Jan. 9, 2012 – ZELTIQ Aesthetics, Inc. (NASDAQ:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today the retirement of Chief Financial Officer John Howe.
Joshua Brumm has been named Vice President and Chief Financial Officer. Mr. Brumm was previously Vice President of Corporate
Development & Investor Relations. Mr. Howe has agreed to make himself available to ZELTIQ in an advisory capacity to assist in a smooth and complete transition.
Gordie Nye, President and Chief Executive Officer, said, “John Howe has been instrumental to the formation and performance of ZELTIQ as a commercial enterprise. He and I partnered closely to craft the commercial strategy, and we believe it has succeeded. We thank John for his contributions during our rapid growth as a startup company and wish him well in retirement. Josh Brumm is the natural and optimal candidate to assume the CFO position. He has been a tremendous asset in defining our worldwide market opportunity, building our strategic business model, creating our international sales infrastructure, and was instrumental in completing ZELTIQ’s IPO. He has a deep understanding of our
business, financial profile, and technology. These attributes provide the management and Board of Directors with full confidence in his ability to assume this new leadership role. ”
The company will present at the 30 Annual J.P. Morgan Healthcare Conference, being held on Monday, January 9, 2012 at 1 p.m. ET/10 a.m. PT. An audio webcast of the Company’s presentation will be available by visiting the investor relations section of ZELTIQ’s website at www.coolsculpting.com. A replay of the presentation will be available for 30 days.
About ZELTIQ Aesthetics
We are a medical technology company focused on developing and commercializing products utilizing our proprietary controlled-cooling technology platform. Our first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes our patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. We developed CoolSculpting to safely, noticeably, and measurably reduce the fat
layer within a treated fat bulge without requiring the patient to diet or exercise.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements relating to the company’s operations and operating results. You should not place undue
reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some
cases, beyond our control and that could materially affect actual results. Factors that could materially affect our financial results are
®
th
included in its Securities and Exchange Commission filings, including the risks identified under the section captioned “Risk Factors” in our
quarterly report on Form 10-Q for the quarter ended September 30, 2011. We expressly disclaim any obligation to update information
contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
CONTACTS:
Josh Brumm
ZELTIQ Aesthetics, Inc.
Chief Financial Officer
925-474-2500
Nick Laudico
The Ruth Group
646-536-7030
nlaudico@theruthgroup.com
Seeking Alpha article from last October:
http://seekingalpha.com/article/299507-ipo-preview-zeltiq-aesthetics
Hillary Kramer's GameChanger recommends a BUY under $13 for a target price of $17.50
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
87
|
Created
|
02/03/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |